Stockscreener 앱 받기
7.46
1.71%
-0.13
시간 외 거래:
7.47
0.010
+0.13%
Grifols Sa Adr 주식(GRFS)의 최신 뉴스
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - AD HOC NEWS
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com Canada
Grifols falls 6% after skipping 2026 revenue target; €7.52 bln sales - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - AD HOC NEWS
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
Judge Trims Most, But Not All, Of Grifols Suit Over Share Price - Law360
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar Australia
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
0.46%
0.23%
자본화:
|
볼륨(24시간):